BrainStorm Therapeutics
- Company typePrivate
- Founded2020
- HeadquartersSan Diego, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
BrainStorm Therapeutics firmographics
Firmographics- Name
- BrainStorm Therapeutics
- Legal name
- BrainStorm Therapeutics, Inc.
- Website
- https://brainstormtherapeutics.org
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
BrainStorm Therapeutics industry classification
Industry- Product category
- CNS Drug Discovery
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)
- akta.pro secondary industries
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)
Keywords
Where BrainStorm Therapeutics is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
BrainStorm Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Foundation Grants: LouLou Foundation grant supporting the Parkinson's and rare epilepsy AI discovery collaboration between BioSymetrics and BrainStorm Therapeutics.
- Government Defense Contracts: Revenue-generating multi-year defense collaboration secured through BioSymetrics for AI-enabled chemical threat assessment with the U.S. government. Referenced in Lunai Bioworks shareholder letter as a revenue-generating contract.
Go-to-market motion3 records
Distribution channels1 record
Marketing channels5 records
BrainStorm Therapeutics product offering
Product offeringCore offering
BrainStorm Therapeutics operates a drug discovery platform that combines patient-derived iPSC brain organoid disease models with deep learning, network medicine, and foundation models (e.g., NVIDIA BioNeMo Geneformer) to identify, validate, and de-risk therapeutic targets and candidates for CNS and rare neurological disorders. The platform enables high-throughput screening of thousands of drug molecules per day on human brain cells and is designed to produce development-ready neurology programs for pharmaceutical partnering, licensing, and downstream development.
Product overview
BrainStorm Therapeutics offers a unified AI-powered drug discovery platform centered on human patient iPSC-derived brain organoid technology. The platform integrates advanced computational tools including deep learning and network medicine with living 3D brain organoid models to discover and develop therapeutic candidates for neurological disorders. The platform enables high-throughput screening of thousands of drug molecules per day using clinically translatable disease endpoints, with a current focus on Parkinson's disease, rare genetic epilepsies, and neurodevelopmental disorders like Rett syndrome and CDKL5 deficiency disorder. Through collaborations with partners like BioSymetrics (Lunai Bioworks), the company generates development-ready neurology programs designed for pharmaceutical partnering and downstream development.
Differentiator
Problem solved
Functional benefit
Products and services
- Brain Organoid Drug Discovery Platform Proprietary AI-powered platform combining human patient iPSC-derived brain organoid disease models with deep learning and network medicine to identify therapeutic candidates that halt, prevent, or reverse synaptic network dysfunction and neurodegeneration for complex neurological disorders. Designed for pharmaceutical partnering and licensing.
- Foundation Model-Based Organoid Network Browser Proprietary multimodal data infrastructure and browser for exploring organoid network data, integrating cell sequencing, imaging, and EEG-like brain wave data from organoid experiments.
Quantifiable outcome
- Screened thousands of drug molecules per day directly on human brain cells
- +2 more outcomes
Companies that use BrainStorm Therapeutics
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles3 records
BrainStorm Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability8 records
Feature6 records
BrainStorm Therapeutics partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and major.
- Lunai Bioworks (BioSymetrics)coreBioSymetrics (wholly owned subsidiary of Lunai Bioworks) and BrainStorm Therapeutics launched a foundation-funded strategic collaboration to jointly discover and advance novel therapeutic targets for Parkinson's disease and rare genetic epilepsies. The partnership combines BioSymetrics' AI-driven target discovery and in vivo zebrafish validation platform with BrainStorm's human-derived organoid systems, initially focusing on rare genetic epilepsies and Parkinson's disease. Supported by a LouLou Foundation grant.
- NVIDIAcoreBrainStorm's AI models run on NVIDIA GPUs in the cloud using the NVIDIA BioNeMo Framework. The company is a member of NVIDIA Inception, a global network of cutting-edge startups. BrainStorm used Geneformer model available through BioNeMo for gene expression analysis and is collaborating with the NVIDIA BioNeMo team to optimize open-source access to Geneformer.
- CURE5 FoundationmajorBrainStorm's next major project is an initiative with the CURE5 Foundation to conduct the most comprehensive repurposed drug screen to date for CDKL5 Deficiency Disorder, a rare genetic neurodevelopmental disorder.
- Dr. Alysson Muotri (UCSD)coreDr. Alysson Muotri, professor at UCSD and creator of the first human organoid models for neurodevelopmental disorders, serves on the company's Scientific Advisory Board. He directs the Stem Cell Program and Archealization Center at UCSD and is co-director of the new Gene Therapy Initiative.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
BrainStorm Therapeutics competitors and assessment
Company assessmentOthers
- Molecular Devices: Molecular Devices provides high-content imaging and FLIPR-style screening instruments used in organoid-based drug screening. BrainStorm uses FLIPR-based imaging, making Molecular Devices an enabling infrastructure peer in the workflow.
Direct peers
- Newcells Biotech: Newcells Biotech offers iPSC-derived organoid models, including neural organoids, for drug discovery and toxicity testing. It is a comparable organoid-platform peer serving pharma R&D clients.
- Insitro: Insitro combines machine learning with high-throughput biology (including iPSC-derived disease models) for drug discovery. It targets pharma partnerships in CNS and metabolic disease, directly overlapping with BrainStorm's AI-driven CNS drug discovery thesis.
- Verge Genomics: Verge Genomics applies AI/ML to human CNS disease data to identify novel therapeutic targets, with partnerships in ALS and Parkinson's. It is a direct AI-CNS-discovery competitor pursuing pharma licensing deals.
- StemoniX (Vyant Bio): StemoniX pioneered iPSC-derived brain organoids for drug discovery and is now part of Vyant Bio, where BrainStorm CEO Robert Fremeau previously served as CSO. It is the most direct functional peer given shared organoid platform technology and overlapping pharma customer base.
- bit.bio: bit.bio develops iPSC-derived human cell types including neural cells for drug discovery and disease modeling. It competes with BrainStorm in providing consistent, scalable human neural models for pharma screening programs.
Broad incumbents
- Recursion Pharmaceuticals: Recursion is a leading AI-driven drug discovery company combining high-throughput biology with machine learning, with established multi-program pharma partnerships (Roche, Genentech, Bayer). It represents a much larger-scale competitor in the AI-discovery space.
- FUJIFILM Cellular Dynamics: FUJIFILM Cellular Dynamics is a leading provider of iPSC-derived cells and neural disease models for drug discovery. Blake Anson, BrainStorm's business development lead, was previously Senior Director there, and the company's iPSC-derived CNS models directly overlap with BrainStorm's organoid offerings.
- Charles River Laboratories: Charles River is a major preclinical CRO offering iPSC-derived cell and organoid services for CNS drug discovery. It competes with BrainStorm for pharma preclinical partnership business and offers broader integrated services.
Emerging players
- CAMP4 Therapeutics: CAMP4 Therapeutics applies regulatory RNA biology to CNS disorders, and Robert Fremeau previously served as Executive Director there. It represents an adjacent CNS platform peer with overlapping leadership pedigree and target-validation focus.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
BrainStorm Therapeutics social profiles
Digital presenceBrainStorm Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
BrainStorm Therapeutics leadership team
Management profileNumber of profiles
Profiles7 records
BrainStorm Therapeutics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BrainStorm Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BrainStorm Therapeutics
What does BrainStorm Therapeutics do?
BrainStorm Therapeutics operates a drug discovery platform that combines patient-derived iPSC brain organoid disease models with deep learning, network medicine, and foundation models (e.g., NVIDIA BioNeMo Geneformer) to identify, validate, and de-risk therapeutic targets and candidates for CNS and rare neurological disorders. The platform enables high-throughput screening of thousands of drug molecules per day on human brain cells and is designed to produce development-ready neurology programs for pharmaceutical partnering, licensing, and downstream development.
Is BrainStorm Therapeutics a public or private company?
BrainStorm Therapeutics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was BrainStorm Therapeutics founded?
BrainStorm Therapeutics was founded in 2020. It employs 1 to 10 people.
Where is BrainStorm Therapeutics based?
BrainStorm Therapeutics is headquartered in San Diego, United States, in the North America region.
How does BrainStorm Therapeutics make money?
Two revenue lines are on record. Foundation Grants are the primary driver. The others are government Defense Contracts.
Who are BrainStorm Therapeutics's main competitors?
Molecular Devices is listed as an others. Direct peers are Newcells Biotech, Insitro, Verge Genomics, StemoniX (Vyant Bio) and bit.bio. Broad incumbents are Recursion Pharmaceuticals, FUJIFILM Cellular Dynamics and Charles River Laboratories. CAMP4 Therapeutics is listed as an emerging player.
Does BrainStorm Therapeutics have an API?
No public API is recorded for BrainStorm Therapeutics.
What industry is BrainStorm Therapeutics in?
BrainStorm Therapeutics's product category is CNS Drug Discovery. Its primary akta.pro industry code is HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 8731.